Company / Return on Assets (ROA)
Revolution Medicines, Inc. Return on Assets (ROA) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-48.0%
FY2025
5-year range
-48.0% / -6.5%
FY2021-FY2025
Trend
-104.8%
vs FY2024
Sector context
#173 of 213
Health Care
What the data says
Revolution Medicines, Inc.'s return on assets (roa) of -48.0% is lower than 81% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has declined for 4 consecutive years, from -6.5% in FY2021 to -48.0% in FY2025.
Based on SEC 10-K filings.
-48.0% in FY2025 with a 5-year CAGR of -40.7%.
Declined from -21.2% to -48.0% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -34.7pp
- 5-Year Change
- -40.7pp
- 10-Year Change
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 213This company -48.0% Sector average -24.2%
▼
-98.8% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s return on assets (roa) has declined for 4 consecutive years.
- In FY2025, return on assets (roa) decreased 104.8% year-over-year.
- Currently 23.9pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -48.0% | -104.8% |
| FY2024 | -23.5% | -10.8% |
| FY2023 | -21.2% | -58.9% |
| FY2022 | -13.3% | -106.2% |
| FY2021 | -6.5% | +12.2% |
| FY2020 | -7.4% | +65.9% |
| FY2019 | -21.6% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026